Skip to content

An open-label Phase 3 study of S-474474 in patients with essential hypertension - Evaluation of the safety and efficacy of long term use -

An open-label Phase 3 study of S-474474 in patients with essential hypertension - Evaluation of the safety and efficacy of long term use -

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221437
Enrollment
Unknown
Registered
2011-04-21
Start date
2011-04-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Sponsors

SHIONOGI & CO., LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with essential hypertension who meet the following criteria: Untreated patients whose seated systolic blood pressure is not less than 160 mmHg, or seated diastolic blood pressure is not less than 100 mmHg, and systolic blood pressure is lower than 180 mmHg, and diastolic blood pressure is lower than 110 mmHg, etc.

Exclusion criteria

Exclusion criteria: Patients with renal, hepatic or heart disease

Design outcomes

Primary

MeasureTime frame
Adverse events and adverse drug reactions, etc

Secondary

MeasureTime frame
Change in trough seated systolic and diastolic blood pressure

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026